Skip to main content
. 2016 Oct 18;8(3):63–77. doi: 10.3727/215517916X693366

Figure 1.

Figure 1

Evaluation of the clinical signs at different times: baseline (A–D), short term (A′–D′; 28 days), and long-term (A″–D″; 12 months) after allogeneic mesenchymal stem cell (MSC) transplantation. Right eye dog number 2 (A, A″): clinical signs before MSC transplantation [baseline (BL)]: eye with severe keratoconjunctivitis sicca (KCS) and Schirmer tear tests (STTs) of 2 mm/min, severe ocular discharge (+++), hyperemia (+++), corneal opacity (++), and vascularization (++) (A). Twenty-eight days after MSC transplantation, an improvement was observed on ocular discharge (+), hyperemia (++), corneal opacity (+), and vascularization (+) (A′). The improvement was maintained for up to 12 months, with absence of ocular discharge (−), hyperemia (−), and corneal vascularization (−), although central corneal opacity was still present (+) (A″). Left eye dog number 1 (B, B″): clinical signs before MSC transplantation (BL): mild–moderate KCS and STT of 6 mm/min, severe ocular discharge (+++), moderate hyperemia (++), mild corneal opacity (+) (B), and absence of corneal vascularization (−). Same animal 28 days after MSC transplantation presented mild ocular discharge (+) and absence of hyperemia, although corneal opacity was still present (+) (B′). The improvement was maintained for up to 12 months after MSC transplantation, and absence of ocular discharge and hyperemia was reported, although corneal opacity was still present (+) (B″). Right eye dog number 4 (C, C″): at BL, the eye presented mild–moderate KCS and STT of 7 mm/min, ocular discharge (+), hyperemia (+++), corneal opacity (+), and vascularization (+) (C). Twenty-eight days after MSC transplantation, the eye had no ocular discharge (−); however, the other signs are still present (C′). A greater improvement was observed 12 months after MSC transplantation, when there was absence of all clinical signs (C″). Right eye dog number 8 (D, D″): clinical signs before MSC transplantation (BL): moderate KCS and STT of 12 mm/min, severe ocular discharge (+++), mild hyperemia (+), severe corneal opacity (+++), and moderate vascularization (++) (D). Twenty-eight days after MSC transplantation, there was an improvement in ocular discharge (+), hyperemia (−), and corneal opacity (++). However, vascularization did not improve (++) (D′). At the 12-month follow-up, improvement was maintained, with the absence of hyperemia (−), but ocular discharge (+), corneal opacity (++), and vascularization (++) still being present (D′).